Latest Options News

Argent BioPharma has signed a binding agreement to acquire AusCann’s 48% stake in CannPal, enhancing its clinical and intellectual property assets for CannEpil®. The deal includes an option for the Neuvis® drug-delivery platform and aligns with Argent’s U.S. dual-listing ambitions.

Bluescope Steel has announced a special unfranked dividend of AUD 1.00 per share, payable in late February 2026, signaling a notable return to shareholders outside its regular dividend schedule.

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.

AVITA Medical reported solid 11% revenue growth in 2025 and secured a $60 million credit facility to fuel its next phase of expansion, projecting up to 19% revenue growth in 2026.

Deep Yellow Limited confirms Greg Field will start as Managing Director and CEO on 2 February 2026, marking a leadership transition as the company advances its uranium projects in Namibia and Australia.

AuKing Mining announces the immediate retirement of two board members and reveals a legal dispute involving Orion Resources over the Cloncurry Gold Project, leading to a halt in their planned acquisition.

NeuroScientific Biopharmaceuticals reports encouraging clinical responses in fistulising Crohn’s disease patients treated under Australia’s Special Access Scheme, setting the stage for pivotal Phase 2 trials later this year.

Whitefield Income Limited has announced fully franked monthly dividends for the first quarter of 2026, alongside a half yearly top-up dividend, delivering a solid yield based on recent share prices.

Catalina Resources has strategically reshaped its portfolio by acquiring the Breakaway Dam copper project and the Auric North gold portfolio, while divesting its Laverton assets to sharpen its focus on scalable growth opportunities.

AdAlta Limited has raised A$1.2 million through a strategic placement to advance its innovative PD1 armored MSLN CAR-T therapy for solid cancers, reinforcing its unique 'East to West' cellular immunotherapy approach.

Taruga Minerals reports rock chip assays up to 23.2 g/t gold from its maiden due diligence visit to the Weioko gold district in Papua New Guinea, confirming a robust epithermal gold system with promising exploration upside.

Forrestania Resources has agreed to acquire Catalina Resources’ Laverton Project, swapping its Breakaway Dam copper asset and gaining a significant equity stake in Catalina. This move strategically broadens Forrestania’s presence in the Eastern Goldfields gold belt.